Patent · US Expired

Cancer treatment

US6290929A · kind A · utility

36Cited by
1References
37Claims
0Family size

Assignee

Inventor

Key dates

Filing dateJul 28, 2000
Grant dateSep 18, 2001
Priority date
Expiry dateJul 28, 2020

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61P43/00
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

This invention is a method of treating cancer, including carcinomas and sarcomas, through the administration of a pharmaceutical composition containing an arylaldehyde 5-oxo-1,2,4-triazine hydrazide derivative. The arylaldehyde 5-oxo-1,2,4-triazine hydrazide derivative is selected from the group consisting of those with the formula: ##STR1## wherein R and R.sub.1 are independently selected from the group consisting of hydrogen and alkyl wherein the alkyl group has up to 7 carbon atoms; or a pharmaceutical salt thereof; a prodrug thereof; a metabolite thereof; and mixtures thereof. Pharmaceutical compositions comprising these compounds and their use in various treatment methods are claimed. The compounds can be used in conjunction with other chemotherapeutic agents and potentiators.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.